Back HIV/AIDS

HIV / AIDS

CROI 2016: High STI Rates Among Gay Men on PrEP Supports More Frequent Monitoring

Participants taking tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) continued to have high rates of sexually transmitted infections (STIs) in 2 U.S. PrEP demonstration projects, according to a pair of reports at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. Semi-annual STI testing missed many cases, leading researchers to suggest that gay men on PrEP could benefit from screening every 3 months.

alt

CROI 2016: Rapid Rise in PrEP Awareness in U.S. Gay Men, But Only 5% Have Used PrEP

Large internet surveys of American gay men show that the proportion who have heard of pre-exposure prophylaxis (PrEP) jumped from 45% in 2012 to 68% in 2015, with around half of men willing to consider using PrEP -- but that actual usage is far lower and remains concentrated in a few key urban areas where public health authorities have facilitated its uptake, according to data presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.

alt

CROI 2016: Tailored Support Encourages Black Gay Men to Stay on PrEP

Providing culturally tailored counseling and support programs for black men who have sex with men can increase their likelihood of maintaining adherence to pre-exposure prophylaxis (PrEP) for HIV prevention, helping to address a key public health gap in the U.S., according to findings from the HPTN 073 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston.

alt

CROI 2016: PopART Shows Feasibility of Reaching 90-90-90 HIV Testing and Treatment Targets

Early findings from the PopART study of the impact of a test-and-treat strategy on antiretroviral treatment coverage and HIV incidence show that after one round of household-based testing, linkage to care, and offer of immediate antiretroviral therapy, 90% of adults knew their HIV status and 71% of adults diagnosed with HIV were on treatment, according to preliminary findings presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston. The primary outcome of the study -- the impact of expanded treatment coverage on HIV incidence -- is expected to be reported in mid-2018.

alt

CROI 2016: Removing Clinic Barriers to Rapid ART in Uganda Enables 70% to Start on Same Day

Making point-of-care CD4 T-cell count diagnostics available, revising adherence counseling requirements, and giving extra training to healthcare workers can almost quadruple the number of patients who begin antiretroviral therapy (ART) on the day that they are eligible, Gideon Amanyire of Makerere University reported at the at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. The package of health system reforms was provided to a typical "real world" group of clinics in Uganda and was embedded in everyday practice, suggesting that the same intervention could have a similar impact elsewhere.

alt

CROI 2016: Cotrimoxazole Prophylaxis Provides No Benefit for HIV-Exposed Uninfected Children

Challenging current guidelines, prolonged use of cotrimoxazole may not be necessary for HIV-exposed but uninfected children in low-mortality, non-malarial settings with low risk for late mother-to-child transmission throug breastfeeding, Roger Shapiro told participants at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

March 10 Is National Women and Girls HIV/AIDS Awareness Day

Thursday, March 10, is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), an annual opportunity to call attention to the impact of HIV and AIDS on women and girls worldwide. This year's theme is "The Best Defense Is a Good Offense."

alt